DGAP-News: ALK: GRAZAX(r) long-term trial highlighted as editor's choice in leading scientific journ
(businesspress24) - ALK-Abelló02.03.2012 12:14
---------------------------------------------------------------------------
Summary: Landmark results showing the long-term disease modifying effect of
GRAZAX(r) are published in the American Journal of Allergy and Clinical
Immunology and highlighted as the editor's choice. The trial is the only
published large double-blind placebo-controlled trial to demonstrate that grass
allergy immunotherapy tablets (AIT) is an efficacious treatment for grass
pollen induced allergic rhinitis with sustained effect for at least two years
after treatment completion.
Copenhagen, 2012-03-02 12:13 CET (GLOBE NEWSWIRE) --
In the March issue of the Journal of Allergy and Clinical Immunology (JACI -
the official publication of the American Academy of Allergy, Asthma, and
Immunology) a scientific article by professor Durham et al. on the sustained
effect on allergy symptoms of GRAZAX(r) after completion of three years of
treatment is published. JACI is by impact factor the highest-ranking scientific
journal in the field of allergy.
In addition, the article is highlighted as the editor's choice. Henrik Jacobi,
Executive Vice President of R&D at ALK says: 'This landmark trial with GRAZAX(r)
is a key achievement in the development of modern allergy immunotherapy and we
are proud that the results receive this recognition by JACI. GRAZAX(r) is the
only grass AIT with an approved label for long-term efficacy and a
disease-modifying effect. In total, 17 randomised clinical trials involving
more than 4,300 subjects have been completed and the trials consistently
demonstrate the clinical benefits of this new innovative grass allergy
treatment.'
GRAZAX(r) was approved in Europe in 2006 and is currently marketed in all major
European markets. ALK's partner, Merck (known as MSD outside the USA and
Canada), holds the exclusive product rights in North America. Merck has
submitted a registration application for grass AIT to Health Canada and plans
to submit a registration application for grass AIT to the U.S. Food and Drug
Administration in 2013.
This long-term trial is the first and largest double-blind placebo-controlled
trial to demonstrate that grass allergy immunotherapy tablets (AIT) is an
efficacious treatment for allergic rhinitis and that it induces long-term
clinical and immunological tolerance. The newly published data demonstrates
consistency throughout the three-year treatment period and the two years
following treatment completion. The trial was conducted in eight European
countries during 2004-2010. GRAZAX(r) is the most extensively documented allergy
immunotherapy product currently available and considerable post-marketing
experience has been achieved.
GRAZAX(r) has also been shown to alleviate symptoms of asthma in children and the
product is currently being investigated in the GRAZAX(r) Asthma Prevention (GAP)
trial involving 800 children.
For further information please contact:
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is the world leader in allergy
immunotherapy - a unique treatment of the underlying cause of allergy. The
company has approximately 1,800 employees with subsidiaries, production
facilities and distributors worldwide. ALK has entered into partnership
agreements with Merck and Torii Pharmaceutical Co. Ltd. to commercialise
allergy immunotherapy tablets in North America and Japan, respectively. The
company is headquartered in Hoersholm, Denmark, and listed on the NASDAQ OMX
Copenhagen A/S.
Find more information at www.alk-abello.com.
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=381362
News Source: NASDAQ OMX
02.03.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: ALK-AbellóDenmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0060027142
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.03.2012 - 06:14 Uhr
Sprache: Deutsch
News-ID 586874
Anzahl Zeichen: 0
Kontakt-Informationen:
Ansprechpartner:
Stadt:
Telefon:
Kategorie:
Wirtschaft (allg.)
Anmerkungen:
Diese Pressemitteilung wurde bisher 139 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: ALK: GRAZAX(r) long-term trial highlighted as editor's choice in leading scientific journ"
steht unter der journalistisch-redaktionellen Verantwortung von
ALK-Abelló (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
